Parkinson’s disease is a progressive neurodegenerative disorder that results from the gradual death of certain dopamine producing neurons that aid in regulating motor control, among other functions. As the disease progresses, motor function gradually worsens until a patient is no longer able to perform normal daily tasks such as eating, bathing and dressing. In order to compensate for the loss of dopamine, patients are typically treated with oral carbidopa/levodopa therapy. However, as the disease progresses, dopamine levels fluctuate because of variable responses to oral treatment and insufficient levels of dopamine in the brain, causing OFF episodes.
Parkinson’s disease is the second most common neurodegenerative disorder worldwide and over one million people in the United States suffer from Parkinson’s disease. Its prevalence increases with age. It is estimated that over 350,000 PD patients in the United States deal with OFF episodes on a daily basis.
We are currently developing INP103, levodopa, and INP107, carbidopa/levodopa, each administered using our proprietary POD technology for the treatment of OFF episodes in Parkinson’s disease. Current standard of care for the symptomatic treatment of PD is oral levodopa. Carbidopa is co-administered with levodopa to slow levodopa’s rapid metabolism thereby increasing the amount available for the symptoms of Parkinson’s disease. INP103 and INP107 are non-invasive, self- or caregiver-administered, upper nasal therapies designed to provide rapid delivery of levodopa to the brain for the treatment of OFF episodes.